Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

1. Cortes Castan, J.
2. Martín, M.
3. Pernas Simon, S.
4. Gomez Pardo, P.
5. Lopez-Tarruella, S.
6. Gil Martin, M.
7. Manso, L.M.
8. Ciruelos, E.M.
9. Perez Fidalgo, J.A.
10. Hernando, C.
11. Ademuyiwa, F.
12. Weilbaecher, K.
13. Mayer, I.A.
14. Pluard, T.
15. Martinez Garcia, M.
16. Vahdat, L.T.
17. Wach, A.
18. Barker, D.
19. Romagnoli, B.
20. Kaufman, P.A.

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1093/ANNONC/MDY272.277 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus